^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HZX-02-059

    i
    Other names: HZX-02-059
    Company:
    Xiamen University
    Drug class:
    Tubulin inhibitor, PIKfyve inhibitor
    Related drugs:
    over1year
    Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia. (PubMed, Curr Med Sci)
    Overall, these findings suggest that HZX-02-059 is a promising agent for the treatment of B-ALL patients resistant to conventional therapies.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    HZX-02-059